Literature DB >> 3486060

Deficient expression of MHC class II antigens in some cases of human B cell leukaemia.

K Guy, L J Docherty, A E Dewar.   

Abstract

Cells from the peripheral blood of patients with B cell chronic lymphocytic leukaemia (B-CLL) and acute lymphoblastic leukaemia (ALL) were examined for the expression of MHC class II antigens, using a number of monoclonal antibodies (MoAb) including L243 (anti-DR) and TU22 (anti-DQ). There was wide variation in expression of MHC class II antigens in CLL, both from patient to patient and among cells from the same individual. In a number of subjects a significant proportion of the cells had detectable levels of expression of DR antigens but not of DQ antigens. In some cases of ALL although almost all cells were MHC class II positive, DQ expression was undetectable. Differentiation of CLL cells, induced by culturing the cells with 12-0-tetradecanoyl phorbol-13-acetate (TPA), was accompanied by increases in MHC class II expression at the cell surface of up to more than 20-fold, and resulted in detectable expression of DQ antigens on greater than 90% of the cells in all the subjects studied.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486060      PMCID: PMC1577372     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  The human Ia system.

Authors:  R J Winchester; H G Kunkel
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes.

Authors:  A F Williams; G Galfrè; C Milstein
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

3.  Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation.

Authors:  Y Tsujimoto; J Yunis; L Onorato-Showe; J Erikson; P C Nowell; C M Croce
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

4.  T-cell proliferation and expression of MHC class II antigens.

Authors:  G Brown; L Walker; N R Ling; P Richardson; G D Johnson; K Guy; C M Steel
Journal:  Scand J Immunol       Date:  1984-04       Impact factor: 3.487

5.  Differential expression and serologically distinct subpopulations of human Ia antigens detected with monoclonal antibodies to Ia alpha and beta chains.

Authors:  K Guy; V Van Heyningen; B B Cohen; D L Deane; C M Steel
Journal:  Eur J Immunol       Date:  1982-11       Impact factor: 5.532

6.  Differential inhibition of HLA-D- or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants.

Authors:  G P Pawelec; S Shaw; A Ziegler; C Müller; P Wernet
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

7.  Evidence for involvement of the immunoglobulin heavy-chain gene locus in the 8:14 translocation of human B lymphomas.

Authors:  R V McIntosh; B B Cohen; C M Steel; H Read; M Moxley; H J Evans
Journal:  Int J Cancer       Date:  1983-03-15       Impact factor: 7.396

8.  Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells.

Authors:  T H Tötterman; K Nilsson; C Sundström
Journal:  Nature       Date:  1980-11-13       Impact factor: 49.962

9.  Monoclonal antibodies against HLA-DR antigens replace T helper cells in activation of B lymphocytes.

Authors:  R Palacios; O Martinez-Maza; K Guy
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

10.  Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells.

Authors:  S J Korsmeyer; P A Hieter; J V Ravetch; D G Poplack; T A Waldmann; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

View more
  1 in total

1.  B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes.

Authors:  L Matera; R Foa; M Massaia; M Giovarelli; F Veglia; A Cesano; P Lusso; A Piazza; D Santoli
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.